Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19.


Journal

Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626

Informations de publication

Date de publication:
03 Feb 2021
Historique:
received: 26 11 2020
accepted: 26 01 2021
entrez: 4 2 2021
pubmed: 5 2 2021
medline: 13 2 2021
Statut: epublish

Résumé

An increasing number of subjects are recovering from COVID-19, raising the need for tools to adequately assess the course of the disease and its impact on functional status. We aimed to assess the construct validity of the Post-COVID-19 Functional Status (PCFS) Scale among adult subjects with confirmed and presumed COVID-19. Adult subjects with confirmed and presumed COVID-19, who were members of an online panel and two Facebook groups for subjects with COVID-19 with persistent symptoms, completed an online survey after the onset of infection-related symptoms. The number and intensity of symptoms were evaluated with the Utrecht Symptom Diary, health-related quality of life (HrQoL) with the 5-level EQ-5D questionnaire, impairment in work and activities with the Work Productivity and Activity Impairment questionnaire and functional status with the PCFS Scale. 1939 subjects were included in the analyses (85% women, 95% non-hospitalized during infection) about 3 months after the onset of infection-related symptoms. Subjects classified as experiencing 'slight', 'moderate' and 'severe' functional limitations presented a gradual increase in the number/intensity of symptoms, reduction of HrQoL and impairment in work and usual activities. No differences were found regarding the number and intensity of symptoms, HrQoL and impairment in work and usual activities between subjects classified as experiencing 'negligible' and 'no' functional limitations. We found weak-to-strong statistical associations between functional status and all domains of HrQoL (r: 0.233-0.661). Notably, the strongest association found was with the 'usual activities' domain of the 5-level EQ-5D questionnaire. We demonstrated the construct validity of the PCFS Scale in highly-symptomatic adult subjects with confirmed and presumed COVID-19, 3 months after the onset of symptoms.

Sections du résumé

BACKGROUND BACKGROUND
An increasing number of subjects are recovering from COVID-19, raising the need for tools to adequately assess the course of the disease and its impact on functional status. We aimed to assess the construct validity of the Post-COVID-19 Functional Status (PCFS) Scale among adult subjects with confirmed and presumed COVID-19.
METHODS METHODS
Adult subjects with confirmed and presumed COVID-19, who were members of an online panel and two Facebook groups for subjects with COVID-19 with persistent symptoms, completed an online survey after the onset of infection-related symptoms. The number and intensity of symptoms were evaluated with the Utrecht Symptom Diary, health-related quality of life (HrQoL) with the 5-level EQ-5D questionnaire, impairment in work and activities with the Work Productivity and Activity Impairment questionnaire and functional status with the PCFS Scale.
RESULTS RESULTS
1939 subjects were included in the analyses (85% women, 95% non-hospitalized during infection) about 3 months after the onset of infection-related symptoms. Subjects classified as experiencing 'slight', 'moderate' and 'severe' functional limitations presented a gradual increase in the number/intensity of symptoms, reduction of HrQoL and impairment in work and usual activities. No differences were found regarding the number and intensity of symptoms, HrQoL and impairment in work and usual activities between subjects classified as experiencing 'negligible' and 'no' functional limitations. We found weak-to-strong statistical associations between functional status and all domains of HrQoL (r: 0.233-0.661). Notably, the strongest association found was with the 'usual activities' domain of the 5-level EQ-5D questionnaire.
CONCLUSION CONCLUSIONS
We demonstrated the construct validity of the PCFS Scale in highly-symptomatic adult subjects with confirmed and presumed COVID-19, 3 months after the onset of symptoms.

Identifiants

pubmed: 33536042
doi: 10.1186/s12955-021-01691-2
pii: 10.1186/s12955-021-01691-2
pmc: PMC7856622
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

40

Références

Arch Intern Med. 2007 Jun 25;167(12):1312-20
pubmed: 17592106
Nature. 2020 Aug;584(7820):257-261
pubmed: 32512579
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
PLoS One. 2019 Feb 4;14(2):e0211532
pubmed: 30716129
Respirology. 2010 Apr;15(3):543-50
pubmed: 20337995
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Pharmacoeconomics. 2016 Dec;34(12):1277-1297
pubmed: 27581788
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Value Health. 2016 Jun;19(4):343-52
pubmed: 27325326
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Qual Life Res. 2006 Feb;15(1):83-91
pubmed: 16411033
Thromb Res. 2020 Jun;190:45-51
pubmed: 32298840
J Clin Med. 2020 Sep 12;9(9):
pubmed: 32932582
J Clin Epidemiol. 2010 Jul;63(7):737-45
pubmed: 20494804
J Clin Med. 2020 Dec 09;9(12):
pubmed: 33317214
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
J Palliat Med. 2011 Mar;14(3):337-42
pubmed: 21254813
Eur Respir J. 2020 Jul 2;56(1):
pubmed: 32398306
Thorax. 2005 May;60(5):401-9
pubmed: 15860716
Thromb Res. 2019 Jun;178:59-62
pubmed: 30980999
J Pain Symptom Manage. 2017 Mar;53(3):630-643
pubmed: 28042071
Health Qual Life Outcomes. 2004 Sep 20;2:51
pubmed: 15380021

Auteurs

Felipe V C Machado (FVC)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands. felipemachado@ciro-horn.nl.
NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. felipemachado@ciro-horn.nl.
Department of Respiratory Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands. felipemachado@ciro-horn.nl.
Laboratory of Research in Respiratory Physiotherapy (LFIP), Department of Physiotherapy, State University of Londrina (UEL), Londrina, Brazil. felipemachado@ciro-horn.nl.

Roy Meys (R)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Department of Respiratory Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.

Jeannet M Delbressine (JM)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.

Anouk W Vaes (AW)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.

Yvonne M J Goërtz (YMJ)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Department of Respiratory Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.

Maarten van Herck (M)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Department of Respiratory Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.
REVAL Rehabilitation Research Center, BIOMED Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium.

Sarah Houben-Wilke (S)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.

Gudula J A M Boon (GJAM)

Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.

Stefano Barco (S)

Center for Thrombosis and Haemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland.

Chris Burtin (C)

REVAL Rehabilitation Research Center, BIOMED Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium.

Alex van 't Hul (A)

Department of Respiratory Diseases, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Rein Posthuma (R)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Department of Respiratory Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.

Frits M E Franssen (FME)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Department of Respiratory Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.

Yvonne Spies (Y)

Lung Foundation Netherlands, Amersfoort, The Netherlands.

Herman Vijlbrief (H)

Lung Foundation Netherlands, Amersfoort, The Netherlands.

Fabio Pitta (F)

Laboratory of Research in Respiratory Physiotherapy (LFIP), Department of Physiotherapy, State University of Londrina (UEL), Londrina, Brazil.

Spencer A Rezek (SA)

Institute of Therapies and Rehabilitation, Kantonsspital Winterthur, Winterthur, Switzerland.

Daisy J A Janssen (DJA)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.

Bob Siegerink (B)

Center for Stroke Research Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

Frederikus A Klok (FA)

Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
Center for Thrombosis and Haemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Martijn A Spruit (MA)

Department of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Department of Respiratory Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.
REVAL Rehabilitation Research Center, BIOMED Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH